CFD
ADAP

Creative Financial Designs’s Adaptimmune Therapeutics ADAP Stock Holding History

Creative Financial Designs’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-400
Closed -$2K – 1295
2020
Q4 		$2K Hold
400
– – ﹤0.01% 1104
2020
Q3 		$3K Hold
400
– – ﹤0.01% 1002
2020
Q2 		$4K Buy
+400
New +$2.51K ﹤0.01% 893

Other funds holding ADAP

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Creative Financial Designs's ADAP Position: Q1 2021 in Review

Creative Financial Designs sold out of Adaptimmune Therapeutics (ADAP) in Q1 2021, closing a stake of 400 shares — an estimated $2K sold.

Creative Financial Designs first reported a position in ADAP in Q2 2020 and held it in 3 quarters. The position peaked at $4K in Q2 2020. 84 funds tracked by Wall St. Rank hold ADAP as of Q1 2021.

  • Creative Financial Designs reported no remaining Adaptimmune Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Creative Financial Designs sold 400 Adaptimmune Therapeutics shares in Q1 2021, an estimated $2K.
  • Creative Financial Designs first reported a position in Adaptimmune Therapeutics in Q2 2020 and held it in 3 quarters.
  • Creative Financial Designs's Adaptimmune Therapeutics position peaked at $4K in Q2 2020.
  • 84 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q1 2021.

Based on Creative Financial Designs's 13F filing for Q1 2021, filed 19 Apr 2021.